Charles River Laboratories International, Inc. (CRL) SEC Filings & Earnings Calls

Long-term targets are aspirational and subject to significant uncertainties; not projections or guidance.

“The financial targets are not projections and do not constitute financial guidance; they are subject to significant uncertainties and contingencies and are based upon management's current assumptions, which are subject to change.” · word for word

Divestiture execution risk

“Pre-tax loss on CDMO and Cell Solutions Divestiture $181.7 million; net cash paid to buyer $12.4 million.”

NHP supply chain risk

“Acquisition of Cambodian NHP supplier for $507.3 million with $172.3 million deferred consideration.”

Revenue decline risk

“Total revenue declined 2.7% YoY in Q2; all three segments reported lower revenue.”

Revenue still declining YoY despite sequential improvement; RMS segment continues to shrink.

“Revenue decreased 2.7% YoY; RMS organic revenue -1.4%”

Divestitures may reduce future revenue base and create execution risk.

“Completed divestitures of certain European Discovery Services sites as well as the CDMO and Cell Solutions businesses in May 2026.”

Organic revenue decline and margin pressure from higher costs.

“Organic revenue declined 1.5%, non-GAAP operating margin decreased 280 bps.”

Divestiture of CDMO and Cell Solutions businesses completed; loss on assets held for sale $118M.

“Loss on assets held for sale related to the CDMO and Cell Solutions divestiture totaling $118.0 million.” · word for word

Persistent demand weakness in DSA

“We are continuing to see a cautious spending environment from our client base, principally within our DSA segment as the challenging demand environment experienced in the recent prior quarters has persisted.” · word for word

Large impairment from divestiture

“Net loss attributable to Charles River Laboratories International, Inc., common shareholders was $14.8 million ... due principally to the loss on assets held for sale related to the CDMO and Cell Solutions Divestiture of $118.0 million.” · word for word

Declining operating cash flow

“During the three months ended March 28, 2026, our cash flows from operations were $41.1 million compared with $171.7 million for the same period in 2025.” · word for word

Goodwill and Intangible Asset Impairment Risk

“The primary driver of the GAAP decrease were non-cash intangible asset and goodwill impairments of $211.0 million and $165.0 million, respectively, in the fourth quarter of 2025.” · word for word

NHP Supply Chain Risk

“Third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain.” · word for word

Restructuring and Divestiture Execution Risk

“Most recently, we announced the planned divestitures of the contract development and manufacturing products and services (CDMO) and Cell Solutions businesses and certain European sites within the Discovery Services business.” · word for word

CEO Succession Risk

“In connection with the announcement of Ms. Girshick’s appointment as our Chief Executive Officer, effective May 5, 2026, the Company entered into a letter agreement with Ms. Girshick.” · word for word

Divestiture execution risk; potential disruption to ongoing operations.

“subject to customary closing conditions” · word for word

Revenue decline from divestitures may pressure near-term top-line growth.

“reduce reported revenue by slightly more than $200 million in 2026” · word for word

Non-Human Primate Supply Chain Disruption

“We may use forward-looking statements when addressing topics such as: our expectations regarding the availability of non-human primates and our ability to diversify our non-human primate (NHP) supply chain.” · word for word

Demand Slowdown in Biopharma

“While the biopharmaceutical demand environment has been less robust in recent years” · word for word

Significant impairment charges indicate potential overvaluation of acquired assets and ongoing restructuring.

“$376M in impairment charges ($211M intangible, $165M goodwill) in Biologics Solutions and Cell Solutions.”

Margin pressure from higher direct costs and unfavorable mix may persist.

“Non-GAAP operating margin decreased to 18.1% from 19.9% due to lower revenue and higher costs.”

Leadership transition may introduce execution risk, but appointment of an internal candidate (likely) mitigates this.

“Departure of a director or principal officer (CEO/CFO change) with a new CFO appointment.”

RMS headwinds from NHP shipment timing and CRADL occupancy may offset Manufacturing growth.

“Expected improvement in Manufacturing organic revenue growth will be offset by anticipated RMS headwinds from timing of NHP shipments and CRADL occupancy” · word for word

Integration risk from two acquisitions; PathoQuest revenue modest ($15-20M) and not material near-term.

“PathoQuest SAS is expected to generate annual revenue of approximately $15 to $20 million in 2026. The transaction is not expected to have a material impact on Charles River’s 2026 or 2027 GAAP or non-GAAP financial results.” · word for word

Leadership transition risk; activist involvement may signal strategic changes.

“Elliott Investment Management L.P provided limited consent under Cooperation Agreement”

Seasonality in Q4 and early January may impact near-term proposal and booking activity.

“While seasonality during holiday periods in the fourth quarter and in early January may impact near-term proposal and booking activity” · word for word

Regulatory risk from SEC investigation now resolved; no material findings.

“the SEC’s Division of Enforcement...does not intend to recommend an enforcement action”

SEC investigation into NHP supply chain

“On May 16, 2023, we received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting us to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures, and we are cooperating with the ” · word for word

Loss of key CDMO customers

“The decreases in operating income and operating income as a percentage of revenue for the nine months ended September 27, 2025 were primarily driven by the acceleration of amortization expense recognized as a result of a decrease in the remaining useful life of certain CDMO client relationships due to a loss of key customers.” · word for word

Tariff uncertainty

“The extent and duration of these tariffs and the resulting impact on macroeconomic conditions and our business are uncertain and may depend on various factors including, but not limited to, negotiations between the U.S. and affected countries, reciprocal or retaliatory actions imposed by other countries, tariff exemptions, negative sentiment toward U.S. comp” · word for word